Anti-Rheumatic Drugs - Thailand | Statista Market Forecast

The Anti-Rheumatic Drugs market in Thailand is expected to witness a significant growth in the coming years.
By 2024, the projected revenue is estimated to reach US$46.82m.
This suggests a positive outlook for the market in Thailand.
Furthermore, the market is anticipated to showcase a Compound Annual Growth Rate (CAGR) of 0.94% between 2024 and 2029.
This steady growth is expected to result in a market volume of US$49.05m by 2029.
When compared to other countries globally, United States is predicted to generate the highest revenue in the Anti-Rheumatic Drugs market.
In 2024, United States is forecasted to generate a revenue of US$34.70bn.
This highlights the dominant position of the United States in the global market for Anti-Rheumatic Drugs market.
Thailand's growing healthcare industry is driving demand for innovative anti-rheumatic drugs, offering opportunities for pharmaceutical companies to expand their presence in the market.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The demand for Anti-Rheumatic Drugs in Thailand has been on the rise in recent years.

Customer preferences: The increase in demand for Anti-Rheumatic Drugs in Thailand can be attributed to the growing elderly population in the country. As people age, they become more prone to rheumatic diseases, which has led to a surge in demand for these drugs. Additionally, there has been a growing awareness among the Thai population about the importance of early diagnosis and treatment of rheumatic diseases, which has further fueled the demand for these drugs.

Trends in the market: One of the key trends in the Anti-Rheumatic Drugs market in Thailand is the shift towards biologic drugs. Biologic drugs are increasingly becoming popular due to their effectiveness in treating rheumatic diseases. These drugs are designed to target specific parts of the immune system, which makes them more effective than traditional drugs. Moreover, biologic drugs have fewer side effects than traditional drugs, which has made them more appealing to patients.

Local special circumstances: Thailand has a well-established pharmaceutical industry, which has made it easier for pharmaceutical companies to introduce new drugs into the market. Additionally, the Thai government has been actively promoting the use of generic drugs, which has made it easier for patients to access affordable drugs. This has also led to increased competition among pharmaceutical companies, which has resulted in lower prices for Anti-Rheumatic Drugs.

Underlying macroeconomic factors: Thailand has a rapidly aging population, which has led to an increase in demand for healthcare services, including Anti-Rheumatic Drugs. Moreover, the Thai government has been investing heavily in healthcare infrastructure, which has made it easier for people to access healthcare services. Additionally, the country has a growing middle class, which has led to increased spending on healthcare services. These factors have contributed to the growth of the Anti-Rheumatic Drugs market in Thailand.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.